future of glp-1 drugs The in healthcare: Vital's role in enhancing metabolic treatment programs GLP-1 Drugs: Where We Are

Rahim et al., Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors, J

doi: 10.1080/13543776.2023.2274905

These medications significantly decrease appetite and promote early satiety, often leading to substantial reductions in daily food consumption

On GLP-1 drugs, get comfortable with being uncomfortable The great thing about these drugs, says Kessler, is that they allow you to relearn how to eat

doi: 10.1111/j.1742-1241.2011.02656.x

doi: 10.3389/fendo.2022.882998 Received 24 February 2022 Accepted 21 September 2022 Published 10 October 2022 Volume 13 - 2022 Edited by ke Sjholm, Gvle Hospital, Sweden Reviewed by Zhanna Belaya, Endocrinology Research Center, Russia